Common use of Terms Defined Elsewhere Clause in Contracts

Terms Defined Elsewhere. As used in this Agreement, the following capitalized terms are defined in this Agreement as referenced in the following table: Agreement Preamble Bylaws Capitalization Date Change of Recommendation Charter 3.2 5.2(a) 7.2(d) (i)(F) 3.1 Closing 2.1 Closing Date Company Company Approvals Company Disclosure Letter Company Personal Information Company Recommendation Company Tax Representation Letter Continuation Period D&O Insurance Delisting Period Effective Time Exchange Fund FDA FDA Licenses Fundamental Action Governmental Antitrust Entity Interim Period Legal Restraint Material Contract Material Customer Material Vendor Merger Merger Sub Non-Wholly Owned Subsidiary Notice of Redemption Notice Notice Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble 5.4(a) Article V 5.18(l) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Surviving Corporation Tax Representation Letters Third-Party Consents 6.8 Recitals 2.3 7.18(c) 7.8

Terms Defined Elsewhere. As used The following terms are defined elsewhere in this Agreement, the following capitalized terms are defined in this Agreement as referenced in the following tableindicated below: Term Section Adjustment Excess Amount 2.4(d) Adjustment Shortfall Amount 2.4(d) Agreement Preamble Bylaws Capitalization Date Change Allocation Dispute 1.5(a) Allocation Dispute Notice 1.5(a) Allocation Resolution Period 1.5(a) Approval Motion 5.7(a) Approval Order 5.7(a)(i) Arbitrator 2.4(b) Assignment and Assumption Agreement 1.3(b) Assumed Contracts 1.1(a)(vi) Assumed Liabilities 1.1(c) Assumed Real Property Leases 1.1(a)(x) Bankruptcy and Equity Exception 3.3 Bankruptcy Cases Recitals Bankruptcy Code Recitals Bankruptcy Court Recitals Bankruptcy Court Orders 5.7(a)(ii) Benefit Plan 3.11I Bidding Procedures 5.7(a)(ii) Bidding Procedures Order 5.7(a)(ii) ▇▇▇▇ of Recommendation Charter 3.2 5.2(aSale 2.2(a)(i) 7.2(dBooks and Records 5.3(b)(i) (i)(FBreak-Up Fee 7.5(b)(ii) 3.1 Business Recitals Closing 2.1 Closing Date Company Company Approvals Company 2.1 Code 1.5(a) Consent Asset 1.3(c) Conditional Approval Order 7.4(f) D&O Insurance 5.6(a) DinoKing Assumed Liabilities 1.1(c)(iv) DinoKing Insolvency Proceeding Cost 5.18(d) DinoKing Proceeding 5.18 Disclosure Letters Introduction to Article IV Dispute 1.5(b) Escrow Amount 2.3(b) Escrow Funds 2.3(b) Estimated Current Assets 2.3(b) Estimated Current Asset Statement 2.3(b) ERISA 3.11(c) Excluded Assets 1.1(b) Excluded Contracts Recitals Final Allocation Schedule 1.5(a) Final Current Assets 2.4(c) Financial Statements 3.5(a) Good Faith Deposit 1.4(a) Insurance Policies 5.1(b)(xi) Interim Period 5.1(a) Material Contract 3.10 Notice of Objection 2.4(a) Owned Real Property 3.12(a) Outside Date 7.4(j) PacBridge Parties Settlement 5.7(h) Permits 3.8(b) Proposed Allocation Schedule 1.5(a) Purchaser Preamble Purchaser Default Termination 1.4(b)(ii) Purchaser Disclosure Letter Company Personal Information Company Recommendation Company Tax Representation Introduction to Article IV Real Property 3.12(a) Real Property Lease Assignments 2.2(a)(iii) Real Property Leases 3.12(a) Registered Intellectual Property 3.14(a) Review Period 2.4(a) RMST Shares 3.2(b) RMST Securities 3.2(c) Section 338(h)(10) Election 5.10(d) Seller Disclosure Letter Continuation Period D&O Introduction to Article III Seller Employees 5.5(b) Sellers Preamble Service Provider 3.11(c) Title Insurance Delisting Period Effective Time Exchange Fund FDA FDA Licenses Fundamental Action Governmental Antitrust Entity Interim Period Legal Restraint Material Contract Material Customer Material Vendor Merger Merger Sub Non-Wholly Owned Subsidiary Notice of Redemption Notice Notice Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble 5.4(aPolicy 5.16(a) Article V 5.18(l) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Surviving Corporation Tax Representation Letters Third-Party Consents 6.8 Recitals 2.3 7.18(c) 7.8Transferred Employees 5.5(a)

Terms Defined Elsewhere. As used in this Agreement, Each of the following capitalized terms are defined in this Agreement as referenced has the meaning ascribed to such term in the following tableArticle or Section set forth opposite such term: Acquired Company; Acquired Companies 3.3(b) Acquisition Proposal 6.6 Agreement Preamble Bylaws Capitalization Allocation Statement 7.3(i) Applicable Limitation Date Change of Recommendation Charter 3.2 5.2(a7.1 Basket 7.2(c) 7.2(dBusiness Relation 7.7(b) (i)(FBuyer Preamble Cap 7.2(c) 3.1 Closing 2.1 2.3 Closing Date 2.3 Closing Estimate Statement 2.2 Closing Items 2.4(a) Closing Statement 2.4(a) Company Preamble Company Approvals IP 3.11 Company Disclosure Letter Company Personal Information Company Recommendation Company Tax Representation Letter Continuation Period D&O Insurance Delisting Period Employee Benefit Plan 3.16(a) Dispute Notice 2.4(b) Effective Time Exchange Fund FDA FDA Licenses Fundamental Action Governmental Antitrust Entity Interim Period Legal Restraint Date Preamble Estimated Indebtedness 2.2 Estimated Foreign Withholding Amounts 2.2 Estimated Working Capital 2.2 Excess Amount 2.4(c) Financial Statements 3.4(a) Final Indebtedness 2.4(a) Final Foreign Withholding Amounts 2.4(a) Improvements 3.7 Indemnitee 7.2(g) Indemnitor 7.2(g) IRS 3.16(b) ▇▇▇▇▇ Preamble Latest Balance Sheet 3.4(a) Lease 3.7 Leased Real Property 3.7 Material Contract 3.10(b) Material Customer Customers 3.21 Material Vendor Merger Merger Sub Non-Wholly Owned Subsidiary Notice of Redemption Notice Notice Period Vendors 3.21 Monroe Preamble Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble 5.4(a) Article V 5.18(l) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Parent Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Party Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) Pre-Closing Tax Period 7.3(a) -2- Stock Ownership Rep Support Agreement Surviving Corporation Straddle Period 7.3(c) Purchased Units Recitals Restricted Business 7.7(a) Restricted Period 7.7(a) Resolution Period 2.4(b) Sellers Preamble Seller Parties Preamble Subsidiaries 3.3(b) Shortfall Amount 2.4(c) Tax Representation Letters Third-Contest 7.3(d) Terminating Party Consents 6.8 Recitals 2.3 7.18(c8.1(b) 7.8▇▇▇▇ Preamble Units Recitals

Terms Defined Elsewhere. As used in this Agreement, the The following list is a list of additional capitalized terms are defined in used throughout this Agreement as referenced and a reference to the Section hereof in the following tablewhich such term is defined: 1374 Tax 3.10(g) 338(h)(10) Election 6.9(b) 401(k) Plan 6.7(b) Actions 3.20 Agreement Preamble Bylaws Capitalization Date Change Allocation Statement 6.9(d) applicable indemnifying Persons 12.5 Articles of Recommendation Charter 3.2 5.2(aMerger 1.2 Audited Financial Statements 3.7 Bonus Plan 6.7(b) 7.2(dCFIUS 6.4(a) (i)(F) 3.1 Closing 2.1 1.2 Closing Date 1.2 Closing Working Capital 2.4(a) Code 2.2(d) Company Preamble Company Approvals Common Stock Preamble Company Securities 3.2(b) Company Shareholders Preamble Compliance Program 6.9(k)(ii) Confidentiality Agreement 6.2 Continuing Employees 6.7(b) Damages 12.6(a) Deductible Amount 12.1(b) Delaware Law Recitals Determination Date 12.1(a)(iv) Disclosure Letter Company Personal Information Company Recommendation Company Tax Representation Letter Continuation Period D&O Insurance Delisting Period Schedule 3 Dispute Notice 2.4(d) Effective Time Exchange Fund FDA FDA Licenses Fundamental Action 1.2 End Date 11.1(b) ERISA 3.13(a) Escrow Account 2.2(f) Escrow Agent 2.2(f) Escrow Agreement 2.2(f) Escrow Amount 2.2(f) Estimated Closing Balance Sheet 2.4(b) Estimated Working Capital 2.4(b) Estimated Working Capital Adjustment 2.4(b) Exon-▇▇▇▇▇▇ 6.4(a) Financial Statements 3.7 Foreign Benefit Plan 3.13(j) ▇▇▇▇▇▇▇▇▇ Preamble Governmental Antitrust Entity Interim Period Legal Restraint Material Contract Material Customer Material Vendor Authorities 3.6 Hazardous Substance 3.21 Incentive Payments 2.3(b) Incentive Plan 2.3(b) Incentive Unit Holdback Amount 2.2(c)(i) Incentive Unit Payment Amount 2.3(b) Initial Calculation 2.4(c) Initial Closing Balance Sheet 2.4(c) IRS 3.13(a) Knowledge 14.8 Large Customers 3.16 Merger 1.1 Merger Consideration 2.2(a) Merger Sub NonPreamble Most Recent Balance Sheet 3.7 PCBs 3.21 Parent Preamble Parent Claim 12.4 Parent Indemnified Parties 12.1(a) Participant Deferral Liability 6.12 Participant Release 6.12 Parties of Interest Preamble Party of Interest Preamble Payment Instructions 2.2(b) Permits 3.22(b) Phantom Stock Holdback Amount 2.2(c)(ii) Phantom Stock Payment Amount 2.3(c) Phantom Stock Payments 2.3(c) Phantom Stock Plans 2.3(c) Plan 3.13(a) Pre-Wholly Owned Closing Income Tax Returns 6.9(j) Related Party 6.1(u) Representative Preamble Required Consents 6.4(b) Rhode Island Law Recitals RIBCA 1.1 Section 338 Forms 6.9(c) Securities Act 3.4 Seller Expenses 2.3(a) Settlement Accountants 2.4(d) Settlement Notice 2.4(d) Shareholders Agreement 4.3 Straddle Period 12.1(a)(iv) Subsidiary Notice of Redemption Notice Notice Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble 5.4(aSecurities 3.3(a) Article V 5.18(lSupplemental Indemnity Amount 12.2(b) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Surviving Corporation 1.1 Tax Representation Letters Third-Indemnified Party Consents 6.8 Recitals 2.3 7.18(c6.9(l)(i) 7.8Tax Indemnifying Party 6.9(l)(i) Tax Proceedings 6.9(k)(i) Tax Purchase Price 6.9(d) Third Party Claim 12.5 Transfer Taxes 6.9(f) Unaudited Financial Statements 3.7 Working Capital 2.4(a)

Terms Defined Elsewhere. As used in this Agreement, the The following capitalized terms are defined in this Agreement as referenced in the following tablesections of this Agreement: Acquisition Proposal 4.2(b) Affiliate 9.2 Agreement Preamble Bylaws Capitalization Aggrieved Party 7.2(a) ALLL 3.16(a) Balance Sheet Date 3.8(a) Bank Merger Preamble Bank Merger Effective Time 1.4(a) Bank Regulations 1.1 Bank Regulators 9.2 Breaching Party 7.2(a) Certificates 1.3(c)(i) CGLC 1.1(a) Change of Recommendation Charter 3.2 5.2(aControl Benefit 3.17(e) 7.2(d) (i)(F) 3.1 Closing 2.1 1.5 Closing Date 1.5 Closing Financial Statements 4.8 Code 3.13(b) Company Preamble Company Approvals Bank Preamble Company Disclosure Letter Bank Common Stock 1.4(a) Company Personal Information Common Stock 1.3(b) Company Recommendation Entities Premises 3.18(b) Company Tax Representation Letter Continuation Period D&O Insurance Delisting Period Real Property 3.20(c) Company SEC Reports 3.9(b) Company Shareholders’ Meeting 4.3 Company Stock Option Plan 3.6(b) Company Stock Options 3.6(b) Company Bank Regulatory Agreement 3.22(b) CRA 2.7(c) Derivative Instruments 3.19(e)(iv) Determination Date 4.8 Dissenting Shares 1.3(b) Effective Time 1.2 Encumbrance 9.2 Environmental Laws 9.2 Exchange Fund FDA FDA Licenses Fundamental Action Agent 1.3(c)(i) Exchange Act 3.4(a) (a) Governmental Antitrust Entity Interim Period Legal Restraint 2.4(a) (a) Knowledge 9.2 Law 3.4(b) Material Adverse Effect 9.2 Material Contract Material Customer Material Vendor 3.19(a) Merger Preamble Merger Sub Non-Wholly Owned Agreement 1.2 Merger Consideration 1.3(a)(i) Merger Consideration Adjustment 1.3(c)(ii) Parent Preamble Parent’s Agents 5.11 Parent SEC Reports 2.6(a) Permitted Encumbrances 3.20(a) Per Share Merger Consideration 1.3(c)(ii) Person 9.2 Preferred Share Purchase Rights 3.6(b) Required Regulatory Approvals 3.25 Rights Plan 3.6(b) Securities Act 3.5 Shareholder Agreement 6.2(e) Subsidiary Notice of Redemption Notice Notice Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble 5.4(a) Article V 5.18(l) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Surviving Corporation Tax Representation Letters Third-Party Consents 6.8 Recitals 2.3 7.18(c) 7.89.2

Terms Defined Elsewhere. As used in For purposes of this Agreement, the following capitalized terms are defined in this Agreement as referenced have the meanings set forth in the following tablesections indicated: 401(k) Termination Date 7.13(d) Accounting Firm 7.18(h) Action 7.10(a) Aggregate Equity Election Amount 3.1(c)(i) Agreement Preamble Bylaws Capitalization All Equity Exchange Ratio 3.1(c)(i)(B) Alternative Proposal 7.3(i)(i) Amended Parent Opco Limited Partnership Agreement 2.1(e) Antitrust Laws 7.1(a) Antitrust Remedies 7.1(b) Available Cash Amount 3.1(c)(i) Available Equity Amount 3.1(c)(i) Balance Sheet Date 5.9(a) Book-Entry Units 3.2(c) Cash Election 3.3(a) Cash Election Consideration 3.1(c)(i)(A) Cash Election Units 3.1(c)(i)(A) Certificate 3.2(c) Certificate of GP Merger 1 2.1(d) Certificate of GP Merger 2 2.1(d) Certificate of LP Merger 2.1(d) Certificates of Merger 2.1(d) Claim 7.10(a) Closing 2.2 Closing Date 2.2(b) Code Recitals Continuing Employees 7.13(a) Continuing Partnership 7.18(c) EGP Preamble Election 3.3(a) Election Deadline 3.3(c) Election Form 3.3(c) Election Form Record Date 3.3(c) Exchange Agent 3.3(b) Exchange Fund 3.4(a) Excluded Partnership Unit 3.1(c)(i) Financial Advisor 7.3(b) Financing 7.17(a) Financing Related Parties 10.14 Financing Sources 10.14 GP Merger 1 Recitals GP Merger 1 Consideration 3.1(a) GP Merger 1 Effective Time 2.1(d) GP Merger 2 Recitals GP Merger 2 Consideration 3.1(b) GP Merger 2 Effective Time 2.1(d) GP Merger Consideration Allocation 7.18(h) GP Mergers Recitals GP Pre-Closing Distribution 7.23 GP Written Consents 7.16 Indemnification Expenses 7.10(a) Indemnified Parties 7.10(a)(i) Initial Limited Partner 7.20 Intervening Event 7.3(f) Letter of Transmittal 3.4(b) LP Merger Recitals LP Merger Consideration 3.1(c)(i) LP Merger Effective Time 2.1(d) Maximum Amount 7.10(c) Merger Consideration 3.1(c)(i) Merger Sub 1 Preamble Merger Sub 2 Preamble Merger Sub 3 Preamble Merger Subsidiaries Preamble Mergers Recitals MGP Preamble New Plans 7.13(b) Notice Period 7.3(e)(i) Old Plans 7.13(b)(i) Opco Election 3.3(a) Opco Election Consideration 3.1(c)(i)(C) Opco Election Units 3.1(c)(i)(C) Outside Date 9.1(f) Owned Real Property 5.14(a) Parent Preamble Parent Award 3.5(a) Parent Board Recitals Parent Disclosure Letter 4.2(iii) Parent Entities Preamble Parent Financial Statements 6.8(b) Parent Material Adverse Effect Article VI Parent Opco Preamble Parent Opco Tax Protection Agreement 2.1(e) Parent Permits 6.12(b) Parent Preferred Stock 6.2(a) Parent SEC Documents Article VI Partnership Preamble Partnership Board Recommendation 7.2(b) Partnership Change of in Recommendation Charter 3.2 7.3(d)(i)(D) Partnership Disclosure Letter 4.1(iii) Partnership Employee Benefit Plan 5.18(a) Partnership Entities Preamble Partnership Equity Plans 3.5(a) Partnership Income Tax Returns 7.18(f) Partnership Intellectual Property 5.19 Partnership Material Adverse Effect Article V Partnership Material Agreement 5.12(a) Partnership Meeting 5.6(ii)(A) Partnership Organizational Documents 5.1(a) Partnership Parties 10.14 Partnership Permits 5.11(b) Partnership Property 5.14(b) Partnership Proxy Statement 5.6(ii)(A) Partnership Related Party Agreement 5.20 Partnership Related Persons 9.4(f) Partnership Restricted Unit 3.5(a) Partnership SEC Documents Article V Partnership Subsidiary Documents 5.1(a) Partnership Units 5.2(a) 7.2(dPayoff Letter 7.17(c) (i)(FProceedings 5.15 Proposed Allocation 7.18(h) 3.1 Closing 2.1 Closing Date Company Company Approvals Company Disclosure Letter Company Personal Information Company Recommendation Company Tax Representation Letter Continuation Period D&O Insurance Delisting Period Effective Time Exchange Fund FDA FDA Licenses Fundamental Action Governmental Antitrust Entity Interim Period Legal Restraint Material Contract Material Customer Material Vendor Qualified REIT Subsidiary 6.7(ii)(A)(ii) Registration Statement 6.7(ii)(A) Regular Merger Merger Sub Non-Wholly Owned Subsidiary Notice of Redemption Notice Notice Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble 5.4(aConsideration Allocation 7.18(h) Article V 5.18(lSeller Representative 7.18(f) 5.3(bStock Election 3.3(a) 7.18(cStock Election Consideration 3.1(c)(i)(B) 7.11(aStock Election Units 3.1(c)(i)(B) 7.12(bSuperior Proposal 7.3(i)(ii) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Recitals Surviving Corporation EGP Entity 2.1(b) Surviving MGP Entity 2.1(a) Surviving Partnership Entity 2.1(c) Tax Representation Letters Third-Party Consents 6.8 Recitals 2.3 7.18(cMerger Consideration Allocation 7.18(h) 7.8Taxable REIT Subsidiary 6.7(ii)(A)(iii) Termination Fee 9.4(e) Transfer Taxes 7.18(b)

Terms Defined Elsewhere. As used The following terms are defined elsewhere in this Agreement, the following capitalized terms are defined in this Agreement as referenced in the following table: Action 3.5(g) Agreement Preamble Bylaws Capitalization -12- Allocation Methodology 2.9(a) Allocation 2.9(b) Approvals 2.10(a) Asset Purchase Recitals Assignment Agreement and ▇▇▇▇ of Sale 2.8(a)(v) Assumed Liabilities 2.6 Bankruptcy Code 2.13(h) Basket 7.6(a) Business Contracts 2.4(a) Business Covered Person 5.9 Business Litigation Controlling Party 5.6(b) Business Litigation 5.6(a) Business Permits (b) Cap 7.6(a) Claim Notice 7.4(c) Closing Date Change of Recommendation Charter 3.2 2.3 Closing 2.3 Consent 5.12(a) Confidentiality Agreement 5.2(a) 7.2(dControlling Party 7.4(b)(iii) (i)(FCovered Activities 3.10(c) 3.1 Covered Protected Information 3.10(c) Dx Copyright License 2.13(a)(iii) Dx Framework Source Code 2.13(a)(iii) Dx Infringement 2.13(f)(iv) Dx System License 2.13(a)(ii) Dx Test License 2.13(a)(i) Enforceability Limitations 3.2(b) Excluded Assets 2.5 Expiration Date 7.1(a) Foreign Closing 2.1 Closing Date Company Company Approvals Company Disclosure Letter Company Personal Information Company Recommendation Company Tax Representation Letter Continuation Period D&O Insurance Delisting Period Effective Time Exchange Fund FDA FDA Licenses Fundamental Action Governmental Antitrust Entity Interim Period Legal Restraint Material Contract Documents 2.8(a)(vi) Healthcare Laws 3.5(g) HIPAA 3.5(g) Historical Financial Statements 7.4(a) Indemnified Party 7.4(a) Indemnifying Party 7.4(a) Independent Accounting Firm 2.9(b) IP Contracts 3.9(i) Liability Assumption 7.4(b)(i) License Recitals Material Customer Agreement 3.12(a) Material Vendor Merger Merger Sub Customer Agreement 3.13(a) Material Customer 3.12(a) Material Distributor or Reseller Agreement 3.13(c) Material Distributor 3.13(c) Milestone Payment Date 2.2(c)(i) Milestone Payment 2.2(b)(i) -13- [***] Confidential Treatment Requested - Milestone Trigger 2.2(b)(i) Mutual Transfer Agreement 5.4(c) NanoString Board of Directors 3.2(a) NanoString Indemnified Parties 7.3 NanoString Indemnified Party 7.3 NanoString Other Systems 2.13(a) NanoString Preamble NIH Assignment 5.1 NIH License 5.1 NIH Outside Date 5.1 Non-Wholly Owned Subsidiary Controlling Party 7.4(b)(iii) Non-Paying Party 6.3(b) Non-Regulatory Approvals 2.10(b) Non-Transferable Asset 2.10(a) Notice of Redemption Objection 7.4(d) Parties Preamble Party Preamble PEO 5.4(c) Product Licenses 3.5(c) Purchased Assets 2.4 Purchaser’s Allocation Notice Notice 2.9(b) Purchaser’s Allocation 2.9(b) Registered Licensed Intellectual Property 3.9(a) Regulatory Permits 5.1(a) Relevant Matters 8.8(a) Replaced Distributor Contracts 2.10(b) Replaced Distributor Relationship 2.10(b) Replacement Distributor Contracts 2.10(b) Replacement NIH License Agreement 5.1 Retained Liabilities 2.7 Review Committee 2.13(d) Seller Stockholders 3.2(a) Straddle Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble 5.4(a6.3(b) Article V 5.18(l) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Surviving Corporation Tax Representation Letters Third-Party Consents 6.8 Claim Notice 7.4(a) Third-Party Claim 7.4 Transactions Recitals 2.3 7.18(cTransfer Claimant 5.4(d) 7.8Transfer Taxes 6.3(a) Transferred Permits 2.4(d) Transition Period 2.10(b) Unilateral Settlement 7.4(b)(iii) Universal Panel 2.13(a) Update Report 2.2(c)(ii) Veracyte Indemnified Parties 7.2 Veracyte Indemnified Party 7.2 Veracyte SEC Documents 4.6(a) Veracyte Preamble -14- [***] Confidential Treatment Requested -

Terms Defined Elsewhere. As used in this Agreement, the following capitalized terms are defined in this Agreement as referenced in the following table: Agreement Preamble Bylaws 3.2 Capitalization Date 5.2(a) Change of Recommendation 7.2(d)(i)(F) Charter 3.2 5.2(a) 7.2(d) (i)(F) 3.1 Closing 2.1 Closing Date 2.1 Company Preamble Company Approvals 5.4(a) Company Disclosure Letter Article V Company Personal Information 5.18(l) Company Recommendation 5.3(b) Company Tax Representation Letter 7.18(c) Continuation Period 7.11(a) D&O Insurance 7.12(b) Delisting Period 7.17(a) Effective Time 2.2 Exchange Fund 4.3(a)(i) FDA 5.20(a) FDA Licenses 5.20(a) Fundamental Action 7.2(d)(iii) Governmental Antitrust Entity 7.6(b)(ii) Interim Period 7.1(a) Legal Restraint 8.1(c) Material Contract 5.11(a) Material Customer 5.12(a) Material Vendor 5.12(b) Merger Recitals Merger Sub Preamble Non-Wholly Owned Subsidiary 5.2(f) Notice of Redemption 7.13(a) Notice 7.2(d)(iii) Notice Period 7.2(d)(iii) Outside Date 9.2(a) Parent Preamble Parent Approvals 6.4(a) Parent DSU 4.2(f) Parent Option 4.2(a) Parent RSU 4.2(c) Parent Tax Representation Letter 7.18(c) Parent SAR 4.2(e) Parties Preamble Permitted Confidentiality Agreement 7.2(b)(i) Potential Purchasers 7.6(d) Potential Sale Transaction 7.6(d) Privacy and Security Measures 5.18(k) Privacy-Related Contracts 5.11(a)(vi) Proxy Statement 2.1 Preamble 5.4(a) Article V 5.18(l) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep 6.8 Support Agreement Recitals Surviving Corporation 2.3 Tax Representation Letters 7.18(c) Third-Party Consents 6.8 Recitals 2.3 7.18(c7.8 Transaction Litigation 7.15 TRA Terminations 7.13(d) 7.8Vote-Down 9.2(b)

Terms Defined Elsewhere. As used The following terms are defined elsewhere in this Agreement, the following capitalized terms are defined in this as indicated below: Agent 3.2(a) Agent Agreement as referenced in the following table: 3.2(a) Agreement Preamble Bylaws Capitalization Date Change Antitrust Laws 8.2(b) Audited Driveline Financial Statements 8.12(a) Base Premium 8.4(d) Certificate 3.2(b)(ii) Certificate of Recommendation Charter 3.2 5.2(a) 7.2(d) (i)(F) 3.1 Merger 2.3 Closing 2.1 2.2 Closing Date Company Company Approvals Company 2.2 Covered Persons 8.4(a) ▇▇▇▇ Preamble ▇▇▇▇ Board Recitals ▇▇▇▇ Board Recommendation Recitals ▇▇▇▇ Common Stock 6.2(a) ▇▇▇▇ Disclosure Letter Company Personal Information Company Recommendation Company Tax Representation VI ▇▇▇▇ Equity Interests 6.2(a) ▇▇▇▇ Financial Statements 6.7(b) ▇▇▇▇ IP Agreements 6.16(b) ▇▇▇▇ Material Contract 6.14(b) ▇▇▇▇ Permits 6.17(b) ▇▇▇▇ Preferred Stock 6.2(a) ▇▇▇▇ SEC Documents 6.7(a) ▇▇▇▇ Transaction Litigation 8.8 Debt Commitment Letter Continuation Period D&O Insurance Delisting Period 6.24(a) Divestiture Action 8.2(c) Driveline Agreements 5.9(a) Driveline IP Agreements 5.11(b) Driveline Material Contract 5.9(b) Driveline Permit 5.12(b) Effective Time 2.3 Enforceability Exceptions 4.2(a) Exchange Fund FDA FDA Licenses Fundamental Action Governmental Antitrust Entity Interim Period Legal Restraint Material Contract Material Customer Material Vendor 3.2(a) Excluded Information 8.10(c)(iv) Fee Letter 6.23(a) Financing 6.23(a) GKN Preamble GKN Board Recitals GKN Board Recommendation Recitals GKN Disclosure Letter IV GKN Transaction Litigation 8.8 Indemnification Agreements 8.4(a) Merger 2.1 Merger Consideration 3.1(a)(i) Merger Regulation 9.1(d)(i) Merger Sub NonPreamble Merger Sub Common Stock 3.1(b) NYSE 4.4 Required Amount 6.23 ▇▇▇▇▇▇▇▇-Wholly Owned Subsidiary Notice of Redemption Notice Notice Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 ▇▇▇▇▇ Act 6.7(a) SpinCo Preamble 5.4(aSpinCo Board 2.6(a)(i) Article V 5.18(lSpinCo Options 3.4(a) 5.3(bSpinCo PSUs 3.4(d) 7.18(cSpinCo RSUs 3.4(c) 7.11(aSpinCo SARs 3.4(b) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Surviving Corporation Tax Representation Letters Third-Party Consents 6.8 Recitals 2.3 7.18(c) 7.82.1 Transaction Litigation 8.8 Unaudited Interim Driveline Financial Statements 8.12(b)

Terms Defined Elsewhere. As used The following terms are defined elsewhere in this Agreement, the following capitalized terms are defined in this Agreement as referenced in the following tableindicated below: 2017 Bonuses 9.3(a) Acquired Assets 1.1(a) Aggregate Threshold 6.5(b)(ii) Agreed Amount 6.3(b) Agreement Preamble Bylaws Capitalization Antitrust Approvals 4.3(b) Applicable Cap Amount 6.5(b)(i) Assigned Contracts 1.1(a)(iii) Assumed Liabilities 1.1(c) Assumption Agreements 1.1(c) ▇▇▇▇ of Sale 1.3(b)(iii) Business Benefit Plans 2.16(a) Business Employee 9.3(a) Buyer Preamble Buyer FDA Letters 5.3(d) Buyer Group 1.1(a) Buyer Indemnified Parties 6.1 Buyer Plans 9.3(a) Claim Notice 6.3(b) Claimed Amount 6.3(b) Closing 1.3(a) Closing Date 1.3(a) Closing Net Working Capital 1.4(a) Closing Statement 1.4(a) COBRA 9.3(f) Commercial Business Introduction Commercial Business Balance Sheet Date 2.5(b) Confidentiality Agreement 4.2 Contingent Payment 1.2(b) CTAs 2.9(b) Damages 6.1 DOJ 4.3(a) Domain Name Assignment Agreement 1.3(b)(vi) Downward Adjustment Amount 1.4(c)(i) Draft Allocation 8.5 Electronic Delivery 10.7 Employee Benefit Plan 2.16(a) Employment Practices 2.15(b) Environmental Laws 2.19 Environmental Permits 2.19 ERISA 2.16(a) Estimated Net Working Capital 1.2(e) Excluded Assets 1.1(b) Excluded Liabilities 1.1(d) FDA 2.13(b) Final Allocation 8.5 Final Net Working Capital 1.4(b)(iv) FSA Balances 9.3(a) FSA Participants 9.3(a) FTC 4.3(a) Fundamental Representations 6.4(a) Governmental Entity 2.4(b) Hazardous Substances 2.19 Healthcare Laws 2.13(a) HSR Act 2.4(b) Indemnified Party 6.3(a) Indemnifying Party 6.3(a) Inquiry 4.7(a) IP Assignment Agreements 1.3(b)(vii) IP License Agreement 1.3(b)(iv) Lease 2.8(b) Leased Real Property 2.8(b) Material Contract 2.10(a) Material Customers 2.11 Material Suppliers 2.11 New Buyer Employee 9.3(a) Non-Compete Period 9.9(a) Non-Contingent Bonuses 9.3(c) Non-Solicit Period 9.9(b) Objection Notice 1.4(b)(i) Outside Date 7.1(d)(ii) Parties Preamble Party Preamble Patent Assignment Agreement 1.3(b)(v) Permits 1.1(a)(iv) Pre-Closing Period 4.1(a) Registered Business IP 2.9(a) Regulatory Authority 2.13(b) Regulatory Filings 4.3(a) Reimbursement Amount 9.4(c) Related Agreements 2.3 Restricted Names 9.5 Safety Notice 2.13(d) Secured Notes 4.5 Seller Preamble Seller Board 2.3 Seller Change of Recommendation Charter 3.2 5.2(a4.7(a) 7.2(d) (i)(F) 3.1 Closing 2.1 Closing Date Company Company Approvals Company Seller Disclosure Letter Company Personal Information Company Recommendation Company Tax Representation Letter Continuation Period D&O Insurance Delisting Period Effective Time Exchange Fund Article II Seller FDA FDA Licenses Fundamental Action Governmental Antitrust Entity Interim Period Legal Restraint Material Contract Material Customer Material Vendor Merger Merger Sub Non-Wholly Owned Subsidiary Notice of Redemption Notice Notice Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Letters 5.2(g) Seller FSA 9.3(a) Seller Indemnified Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-6.2 Seller Related Contracts Proxy Statement 2.1 Preamble 5.4(aParties 7.2(b)(v) Seller SEC Documents Article V 5.18(l) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble II Seller Termination Fee 7.2(b)(i) 7.6(dSeller Trademarks 9.6 Shire Milestone Payment 9.4(a) 7.6(dSpecified Milestone Payment 9.4(a) 5.18(kStraddle Period 8.1(b)(i) 5.11(a)(viSublease 1.3(b)(xi) 7.3(aSupply Agreements 4.6 Tax Claim 8.4 Third Party Claim 6.3(a) -2- Stock Ownership Rep Support Third Party IP 2.9(b) Trademark Assignment Agreement Surviving Corporation Tax Representation Letters Third-Party Consents 6.8 Recitals 2.3 7.18(c1.3(b)(vii) 7.8Transfer Taxes 8.1(a) Transferred Accounts Receivable 1.1(a)(xiv) Transferred Inventory 1.1(a)(xi) Transferred IP 1.1(a)(iv) Transferred IP Agreements 2.9(b) Transferred IP Documentation 1.1(a)(vi) Transferred Permits 1.1(a)(iv) Transition Services Agreement 1.3(b)(x) Upfront Payment 1.2(a) Upward Adjustment Amount 1.4(c)(ii)

Terms Defined Elsewhere. As used The following terms are defined elsewhere in this Agreement, the following capitalized terms are defined in this Agreement as referenced in the following table: Action 3.5(g) Agreement Preamble Bylaws Capitalization Allocation Methodology 2.9(a) Allocation 2.9(b) Approvals 2.10(a) Asset Purchase Recitals Assignment Agreement and ▇▇▇▇ of Sale 2.8(a)(v) Assumed Liabilities 2.6 Bankruptcy Code 2.13(h) Basket 7.6(a) Business Contracts 2.4(a) Business Covered Person 5.9 Business Litigation Controlling Party 5.6(b) Business Litigation 5.6(a) Business Permits (b) Cap 7.6(a) Claim Notice 7.4(c) Closing Date Change of Recommendation Charter 3.2 2.3 Closing 2.3 Consent 5.12(a) Confidentiality Agreement 5.2(a) 7.2(dControlling Party 7.4(b)(iii) (i)(FCovered Activities 3.10(c) 3.1 Covered Protected Information 3.10(c) Dx Copyright License 2.13(a)(iii) Dx Framework Source Code 2.13(a)(iii) Dx Infringement 2.13(f)(iv) Dx System License 2.13(a)(ii) Dx Test License 2.13(a)(i) Enforceability Limitations 3.2(b) Excluded Assets 2.5 Expiration Date 7.1(a) Foreign Closing 2.1 Closing Date Company Company Approvals Company Disclosure Letter Company Personal Information Company Recommendation Company Tax Representation Letter Continuation Period D&O Insurance Delisting Period Effective Time Exchange Fund FDA FDA Licenses Fundamental Action Governmental Antitrust Entity Interim Period Legal Restraint Material Contract Documents 2.8(a)(vi) Healthcare Laws 3.5(g) HIPAA 3.5(g) Historical Financial Statements 7.4(a) Indemnified Party 7.4(a) Indemnifying Party 7.4(a) Independent Accounting Firm 2.9(b) IP Contracts 3.9(i) Liability Assumption 7.4(b)(i) License Recitals Material Customer Agreement 3.12(a) Material Vendor Merger Merger Sub Customer Agreement 3.13(a) Material Customer 3.12(a) Material Distributor or Reseller Agreement 3.13(c) Material Distributor 3.13(c) Milestone Payment Date 2.2(c)(i) Milestone Payment 2.2(b)(i) Milestone Trigger 2.2(b)(i) Mutual Transfer Agreement 5.4(c) NanoString Board of Directors 3.2(a) NanoString Indemnified Parties 7.3 NanoString Indemnified Party 7.3 NanoString Other Systems 2.13(a) NanoString Preamble NIH Assignment 5.10 NIH License 5.10 NIH Outside Date 5.10 Non-Wholly Owned Subsidiary Controlling Party 7.4(b)(iii) Non-Paying Party 6.3(b) Non-Regulatory Approvals 2.10(b) Non-Transferable Asset 2.10(a) Notice of Redemption Objection 7.4(d) Parties Preamble Party Preamble PEO 5.4(c) Product Licenses 3.5(c) Purchased Assets 2.4 Purchaser’s Allocation Notice Notice 2.9(b) Purchaser’s Allocation 2.9(b) Registered Licensed Intellectual Property 3.9(a) Regulatory Permits 5.1(a) Relevant Matters 8.8(a) Replaced Distributor Contracts 2.10(b) Replaced Distributor Relationship 2.10(b) Replacement Distributor Contracts 2.10(b) Replacement NIH License Agreement 5.10 Retained Liabilities 2.7 Review Committee 2.13(d) Seller Stockholders 3.2(a) Straddle Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble 5.4(a6.3(b) Article V 5.18(l) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Surviving Corporation Tax Representation Letters Third-Party Consents 6.8 Claim Notice 7.4(a) Third-Party Claim 7.4 Transactions Recitals 2.3 7.18(cTransfer Claimant 5.4(d) 7.8Transfer Taxes 6.3(a) Transferred Permits 2.4(d) Transition Period 2.10(b) Unilateral Settlement 7.4(b)(iii) Universal Panel 2.13(a) Update Report 2.2(c)(ii) Veracyte Indemnified Parties 7.2 Veracyte Indemnified Party 7.2 Veracyte SEC Documents 4.6(a) Veracyte Preamble

Terms Defined Elsewhere. As used in this Agreement, the following capitalized terms are defined in this Agreement as referenced in the following table: Agreement Preamble Anti-Corruption Laws 5.5(d) Bylaws Capitalization Date 3.2 Change of Recommendation 7.2(d)(i)(G) Charter 3.2 5.2(a) 7.2(d) (i)(F) 3.1 Closing 2.1 Closing Date 2.1 Company Preamble Company Approvals 5.4(a) Company Disclosure Letter Article V Company Personal Information 5.18(l) Company Recommendation Company Tax Representation Letter Continuation Period 5.3(b) D&O Insurance 7.12(a) Delisting Period 7.18(a) Effective Time 2.2 Exchange Fund FDA FDA Licenses Fundamental Action 4.3(a)(i) Excluded Share 4.1(b) Governmental Antitrust Entity 7.6(b)(ii) Interim Period 7.1(a) Lease 5.17(a) Legal Restraint 8.1(c) Material Contract 5.11(a)(xvi) Material Customer Payor 5.12(a) Material Vendor 5.12(b) Merger Recitals Merger Consideration 4.1(a) Merger Sub Preamble Non-Wholly Owned Subsidiary 5.2(f) Notice of Redemption Notice 7.2(d)(iii) Notice Period 7.2(d)(iii) Original Date 7.4(b) Outside Date 9.2(a) Parent Preamble Parent Approvals Parent DSU 6.4(a) Parent Option 4.2(a)(ii) Parent RSU Parent Tax Representation Letter Parent SAR RSA 4.2(b) Parties Preamble Permitted Confidentiality Agreement 7.2(b)(i) Potential Purchasers 7.6(d) Potential Sale Transaction 7.6(d) Privacy and Security Measures Privacy-Related Contracts Requirements 5.18(k) Proxy Statement 2.1 Preamble 5.4(a) Article V 5.18(l) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Subsidiary Partnership 5.16(o) Surviving Corporation Tax Representation Letters 2.3 Third-Party Consents 6.8 Recitals 2.3 7.18(c) 7.87.8 Transaction Litigation 7.15

Terms Defined Elsewhere. As The following is a list of additional terms used in this Agreement, Agreement and a reference to the following capitalized terms are defined Section hereof in this Agreement as referenced in the following tablewhich such term is defined: Acquisition Sub Preamble Acquisition Sub Company Common Stock 2.8(c) Agreement Preamble Antitrust Laws 5.5 Certificates 2.10(b) Closing 2.3(a) Closing Adjustment 2.14(b) Closing Cash 2.14(a) Closing Cash Target 2.14(a) Closing Consideration Allocation Schedule 2.9(c) Closing Date 2.3(a) COBRA Coverage 3.12(e) Collective Bargaining Agreement 3.17(a) Company Preamble Company Assets 3.5 Company Bylaws Capitalization 2.3(c)(ii) Company Disclosure Schedule Article III: Preamble Company-Owned Intellectual Property 3.18(a) Company Stockholder Approval 3.3(b) Company Warrants 3.4(c) Confidentiality Agreement 5.4(d) Copyrights 3.18(a) DGCL 4.3(a) Dissenting Shares 2.12 DOJ 5.5(b) Early Termination Election 7.1(c) Early Termination Override Notice 7.1(c) Effective Time 2.2 Employee Plans 3.12(a) Employment Agreements 2.3(b)(iv) Estimated Closing Cash 2.14(b) Exchange Act 4.5(a) FCPA 3.25(a) FTC 5.5(b) General Enforceability Exceptions 3.3(a) In-Bound License Agreements 3.6(a)(v) Indemnified Officers 5.7(a) Infringes 3.18(d) Insurance 3.19 Intellectual Property 3.18(a) Letter of Transmittal 2.10(b) License Agreement 3.6(a)(v) Material Contracts 3.6(a) Merger 2.1 Merger Certificate 2.2 Money Laundering Laws 3.25(b) Multi-Employer Plan 3.12(a) Non-Union Employees 5.8(a) NRS 2.1 Out-Bound License Agreements 3.6(a)(v) Outside Date Change of Recommendation Charter 3.2 7.1(b) Parent Preamble Parent SEC Documents 4.5(a) Parent Stockholder Approval 4.3(b) Party Representative 5.2(a) 7.2(dPatents 3.18(a) (i)(FPayoff Letter 2.9(b) 3.1 Pre-Closing 2.1 Closing Date Company Company Approvals Company Disclosure Letter Company Personal Taxes 3.10(a) Real Property Leases 3.7(a) Real Property Permits 3.7(g) Record Retention Period 5.12 Representative Preamble Requested Information Company Recommendation Company Tax Representation Letter Continuation Period D&O Insurance Delisting Period Effective Time Exchange Fund FDA FDA Licenses Fundamental Action Governmental Antitrust Entity Interim Period Legal Restraint Material Contract Material Customer Material Vendor Merger Merger Sub Non5.4(b) ▇▇▇▇▇▇▇▇-Wholly Owned Subsidiary Notice of Redemption Notice Notice Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble 5.4(a▇▇▇▇▇ Act 4.5(a) Article V 5.18(lSEC 4.5(a) 5.3(bSecurities Act 4.5(a) 7.18(cSettlement Accountants 2.13(e) 7.11(aSoftware 3.18(a) 7.12(bSpecial Meeting 5.3(e) 7.17(aStock Plan 3.4(b) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Surviving Corporation Tax Representation Letters Third-2.1 Systems 3.18(o) Third Party Consents 6.8 Recitals 2.3 7.18(cIntellectual Property 3.18(b) 7.8Trade Secrets 3.18(a) Trademarks 3.18(a) Transaction Fee Statement 2.9(a) WARN Act Laws 3.17(d)

Terms Defined Elsewhere. As used In addition to the terms defined in this AgreementSection 1.1, each of the following capitalized terms are is defined in this the Section of the Agreement as referenced in the following tableset forth opposite such term below: Accounting Rules 5.6(b) ADSP 8.7(g) Allocation Schedule 8.7(g) Articles of Merger 2.2 Audited Buyer Financials 7.5(a) Audited Company Financials 5.6(a) Auditor 3.3(d)(i) Bank 5.1(a) Bank Merger 2.7 Bank Merger Agreement 2.7 Bankruptcy and Equity Exceptions 5.2 Basket 10.6(a)(i) BOLI 2.8(a)(ii)(C) Branch Leases 5.12(a)(i) Buyer Preamble Bylaws Capitalization Buyer Appraisal Delivery Date Change of Recommendation Charter 3.2 5.2(a3.4(a) 7.2(dBuyer Covered Losses 10.6(a)(i) (i)(FBuyer Disclosure Schedule Preamble to Article 7 Buyer Indemnitee 10.1 Buyer Losses 10.1 Buyer Plans 8.6(b) 3.1 Cap 10.6(a)(iii) Certificate 2.6(a) Claim Notice 10.3 Closed Branches 8.17 Closing 2.1 4.1 Closing Date 4.1 Closing Payment 3.1(a) Common Interest Information 8.22(c) Company Preamble Company Approvals Appraisal Delivery Date 3.4(c) Company Disclosure Letter Schedule Preamble to Article 5 Company Personal Information Financials 5.6(a) Company Recommendation Plans 5.18(a) Company Tax Representation Letter Continuation Period D&O Insurance Delisting Period Stock Recitals Damages 10.1 Derivative Transactions 5.13 Disclosure Schedule 8.11 Dispute Notice 3.3(b) Disputed Matters 3.3(b) Effective Time Exchange Fund FDA FDA Licenses Fundamental Action Governmental Antitrust Entity 2.2 Environmental Laws 5.17 Environmental Survey 8.21(a) ESOP 5.18(e) Estimated Effective Time Balance Sheet 3.2 FBCA Recitals FHLBA 5.1 Final Losses 10.4(e) Final Net Book Value 3.3(e) First Negotiation Period 3.4(b) Fiserv Contract 2.8(a)(ii)(H) Fraud 10.6(a) FRB 1.1(d) FTMC 5.1(a) FTST 5.1(a) Incumbent Counsel 8.14(a) Indemnified Party 10.3 Indemnifying Party 10.3 Interim Period Legal Restraint Company Financials 5.6(a) IRS 5.18(c) Lien 5.3 Losses 10.6(b) Material Contract Contracts 5.12(b) Material Customer Defect 8.21(d) Material Vendor Defect Notice 8.21(c) Merger Recitals Merger Sub Consideration 3.1(a) Monthly Financials 8.19 Negative True-Up Amount 3.3(e)(ii) Net Book Value 2.8(b) Non-Wholly Continuing Employee 8.6(a) Non-Performing 2.10(b) OCC 1.1(d) Order 5.8 Other Transferred Assets 2.9 Outside Closing Date 11.1(b)(ii) Owned Subsidiary Branch Property 5.16 Parent Preamble Parent Covered Losses 10.6(a)(ii) Parent Disclosure Schedule Preamble to Article 6 Parent Indemnitee 10.2 Parent Losses 10.2 Parties Preamble Permits 5.9 Permitted Real Estate Liens and Exceptions 5.16 Plaintiff Litigation 8.22(a) Policies 5.18 Pool 5.11(g) Positive True-Up Amount 3.3(e)(i) Property Examination 8.21(a) Property Review Appraisal Factors 8.21(c) Property Review Period 8.21(a) Put Date 8.16(c) Put Notice of Redemption Notice Notice 8.16(c) Put Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality 8.16(a) Qualified MAI Appraiser 3.4(a) Regulatory Approval 9.1(c) Representatives 8.3(a) Repurchase Price 8.16(g) Repurchased Loan 8.16(d) Response Period 10.4(a) Revised Effective Time Balance Sheet 3.3(a) Second Negotiation Period 3.4(d) Section 338(h)(10) Election 8.7(f) Servicing Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble 5.4(a) Article V 5.18(l) 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble 5.2(f) 7.13(a) 7.2(d)(iii) 7.2(d)(iii) 9.2(a) Preamble 6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(iShares 2.6 Third Appraiser 3.4(e) 7.6(dThird Party Action 10.4(a) 7.6(dThird Party Action Notice 10.4(a) 5.18(kTransaction Documents 5.2 Transferred Assets 2.8(a)(ii) 5.11(a)(viTransferred Branch Lease 2.8(a)(ii)(D) 7.3(aTransferred Holding Company Assets 2.8(a)(i) -2- Stock Ownership Rep Support Agreement Surviving Corporation Tax Representation Letters Third-Party Consents 6.8 Recitals 2.3 7.18(cTransferred Loans 2.8(a)(ii)(B) 7.8Transferred Personal Property 2.8(a)(ii)(F) Transferred Owned Branch Property 2.8(a)(ii)(E) Transferred Employees 8.6(b) Transferred Loans 2.10(a) Transferred Records 8.4 Transitional Employees 8.6(a) TruPS 2.8(a)(i)(A) TruPS Assumption 8.15 USA PATRIOT Act 5.9